Key result
Fondaparinux and early-stage CRC are linked to increased postoperative bleeding risk.
Why the study?
Pharmacological thromboprophylaxis after colorectal cancer surgery is recommended, but risk factors for postoperative bleeding with fondaparinux or enoxaparin remain unclear.
What are the risk factors for postoperative bleeding in patients receiving pharmacological thromboprophylaxis after elective colorectal cancer surgery?
Observational (n=218)
What are the risk factors for postoperative bleeding in patients receiving pharmacological thromboprophylaxis after elective colorectal cancer surgery?
Fondaparinux and early disease-stage CRC are independent risk factors for postoperative bleeding in patients receiving pharmacological thromboprophylaxis after colorectal cancer surgery.
Fondaparinux may elevate bleeding risk after elective CRC surgery; leaves open optimal prophylaxis choice in early-stage disease.
BACKGROUND: Pharmacological thromboprophylaxis after colorectal cancer (CRC) surgery is internationally recommended for venous thromboembolism (VTE) prevention. The aim of this retrospective study was to evaluate the risk factors of postoperative bleeding after elective surgery for patients with primary CRC receiving pharmacological thromboprophylaxis of fondaparinux or enoxaparin. METHODS: We experienced consecutive 266 patients who underwent elective surgery for CRC during the study period. Finally, the medical records of 218 patients with CRC administrated fondaparinux or enoxaparin following surgery were retrospectively reviewed to evaluate symptomatic VTE until 28 days and postoperative bleeding comparing perioperative D-dimer levels. RESULTS: The significant differences in TNM classification staging and type of thromboprophylaxis were observed between postoperative bleeding-negative and bleeding-positive group. There was no statistical significance among other backgrounds of patients between the two groups. One case (0.46%) of symptomatic VTE and total 11 cases (5%) of postoperative bleeding were observed. In the univariate analysis, fondaparinux thromboprophylaxis and early disease-stage CRC (stages 0 and I) were associated with risk for postoperative bleeding. Multivariate analysis revealed that fondaparinux thromboprophylaxis was identified as an independent risk factor of postoperative bleeding. Moreover, preoperative levels of D-dimer in patients with stage IV CRC were significantly higher than those with the other stages. The significant elevation in preoperative D-dimer was also observed in patients with stage II CRC compared to those with stage I CRC. Perioperative levels of D-dimer in patients with advanced disease-stage CRC (stages II, III, and IV) were significantly higher than those in patients with early disease-stage CRC. CONCLUSIONS: Fondaparinux administration and early disease-stage CRC appeared to be risk factors for postoperative bleeding in patients with pharmacological thromboprophylaxis undergoing surgical treatment for CRC. Patients' hypercoagulative condition depending on disease progression of CRC might be related to the occurrence of postoperative bleeding following CRC surgery.
No takes yet. Share an insight, caveat, or question.
Ohta et al. (2019) conducted an observational in Colorectal cancer (n=218). Fondaparinux thromboprophylaxis vs. Enoxaparin thromboprophylaxis was evaluated on Postoperative bleeding. Fondaparinux administration and early disease-stage CRC were identified as independent risk factors for postoperative bleeding (overall incidence 5%) following elective colorectal cancer surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: